Atrys Health has announced the successful closing of a capital increase aimed at qualified investors for an amount of 35 million euros. The operation has proven the interest of top-tier investors in the company and its sector by registering an over-demand that has reached 105 million euros: that is, three times the amount that the company aspired to raise.
At the end of this expansion, Atrys’ Board of Directors has given priority to the most strategic investors with a greater commitment to accompanying the long-term growth of the company. Several leading current shareholders, such as Onchena, Inversiones Industriales Serpis or Inversiones Inmobiliarias Avilés, as well as the company’s management team have also participated in the round.
In the words of Santiago de Torres, President of Atrys, “this capital increase confirms both the attractiveness of Atrys among qualified investors and that of companies that, like us, operate at the intersection of the health and technology sectors in the post-COVID-19 world. We are very satisfied with the incorporation of new investors and the support of the investors who already accompanied us and have attended this extension.
Atrys published solid results in 2019, with a proforma turnover of 20.8 million and proforma EBITDA of 7 million, 88% and 109% more than the previous year, respectively.
The company recently announced the acquisition of ITMS: a leading telecardiology and teleradiology company with a presence in Chile, Colombia, Brazil and Peru, which in 2019 recorded sales of more than 23 million euros and which has made Atrys a world leader in telemedicine in Spanish language and one of the four largest companies in its sector globally.
